Biodyne Co

Biodyne Co EBIT per Share

The EBIT per Share of Biodyne Co (314930.KQ) as of Nov 3, 2026 is 22.13 KRW. In the previous year, EBIT per Share was -58.68 KRW — a change of -137.71% (higher).

EBIT per Share

22.13KRW

YoY

-137.71%

Last updated:

EBIT per Share of Biodyne Co is 2025 22.13 KRW. EBIT per Share of Biodyne Co was 2024 -58.68 KRW. It decreases by -137.71% higher compared to the previous year.

The Biodyne Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2020
-373.62 KRW
Jan 1, 2021
-398.33 KRW
Jan 1, 2022
1,136.46 KRW
Jan 1, 2023
-69.57 KRW
Jan 1, 2024
-58.68 KRW
Jan 1, 2025
22.13 KRW
Jan 1, 2026 (e)
0.00 KRW
Jan 1, 2027 (e)
0.00 KRW
The Biodyne Co EBIT per Share history
YEAREBIT per ShareYoY
est0.00KRW—
est0.00KRW-100.00%
22.13KRW-137.71%
-58.68KRW-15.65%
-69.57KRW-106.12%
1,136.46KRW-385.31%
-398.33KRW+6.61%
-373.62KRW-1.32%
-378.62KRW-587.94%
77.60KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biodyne Co Stock analysis

What does Biodyne Co do? Biodyne Co., Ltd. develops and sells cancer diagnosis solutions, including LBC diagnostic equipment and diagnostic reagent kits. The company's equipment lineup features PATHPLORER AUTO, PATHPLORER 4.7, PATHPLORER 4.63, and PATHPLORER ECO, targeting healthcare providers in domestic and international markets. Products are sold in Japan, Russia, Portugal, and Thailand, with domestic sales complementing overseas distribution. Revenue is generated through direct sales of diagnostic equipment and reagent kits to medical facilities and laboratories. Biodyne's primary customers are healthcare institutions requiring cancer screening and diagnostic tools, including hospitals and clinical laboratories. The firm's domestic market presence supports its international expansion into regions like Japan and Russia, where demand for advanced diagnostic solutions is growing. Sales of PATHPLORER series equipment and reagent kits form the core revenue streams, with no additional services or licensing models mentioned. The company focuses on a niche segment of cancer diagnostics, leveraging its equipment and reagent kits to serve both local and global healthcare systems. By offering standardized diagnostic solutions, Biodyne caters to the needs of medical professionals seeking reliable and efficient cancer detection methods. International markets such as Portugal and Thailand represent key growth areas alongside established domestic operations. Biodyne Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biodyne Co stock

EBIT per Share of Biodyne Co is 22.13 KRW in 2025.

EBIT per Share of Biodyne Co changed from -58.68 KRW to 22.13 KRW, representing a -137.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Biodyne Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Biodyne Co

All Key Metrics — Biodyne Co